Prescribing information

 

Prescribing information

       

Kymriah® is indicated for the treatment of paediatric and young adult patients up to and including 25 years of age with B-cell acute lymphoblastic leukaemia (ALL) that is refractory, in relapse post-transplant or in second or later relapse, and adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy.1

Preview or download our range of resources specifically designed to help Healthcare Professionals manage patients that have been prescribed with Kymriah.

This page is intended for healthcare professionals. Please do not direct patients to this page.

Please note that these resources are designed for optimal use on desktop or tablet. Functionality may be restricted on some devices, including mobile.

Under heading Training materials for HCPS - Preview of MANAGEMENT GUIDE;

MANAGEMENT GUIDE

This guide provides detailed information about the management of a patient whilst on Kymriah.

Preview

 

Under heading Training materials for HCPS - Preview of HCP TRAINING SLIDES;

HCP TRAINING SLIDES

These training slides provide guidance on when and how to initiate treatment, as well as how to monitor patients successful on treatment.

Preview

 

Under heading Training materials for HCPS - Preview of PHARMACY CELL LAB INFUSION CENTRE TRAINING.

PHARMACY CELL LAB INFUSION CENTRE TRAINING

Guidance on reception storage, handling, thawing, preparation for infusion of Kymriah to mitigate a decrease in cell viability.

Preview

 

Under heading Materials for you to give your patients - Preview of PATIENT AND CAREGIVERS EDUCATIONAL MATERIAL;

PATIENT AND CAREGIVERS EDUCATIONAL MATERIAL

Guidance for patients who have been prescribed with Kymriah, and their caregivers, on what to expect with their treatment and important supporting information.

Preview

 

Under heading Materials for you to give your patients - Preview of PATIENT ALERT CARD.

PATIENT ALERT CARD

An alert card to help improve communication and continuity of care between patients and their treating doctor.

Preview

 

CAR-T, chimeric antigen receptors cell therapy; HCP, healthcare professional.

Reference

  1. Kymriah Summary of Product Characteristics; Novartis Pharmaceuticals UK Ltd.
Rate this content: 
Average: 4 (1 vote)
UK | December 2021 | 144096
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]